-

Abstract

Aim Irritable gastrointestinal system disease which reduces the quality of life due to abdominal pain secondary to defecation change and it has a high prevalence in society. It is known that inflammation and changes in immune system have a role in the pathogenesis of IBS. Materials and Methods In this study, we aimed to investigate retrospectively the erythrocyte and platelet counts of patients with IBS and compare them to those of healthy controls. Files of 30 patients with IBS and 30 healthy people , who consulted to gastroenterology clinic in Namik Kemal University Faculty of Medicine, were scanned. The erythrocyte and platelet counts of these people as well as their demographics were recorded. Results It was seen that RBC, HGB, HCT, MCV, MCH, MCHC, RDWCV and RDWSD levels did not differ in patients with IBS compared with the control group. Similarly, we found that PLT, MPV, PDW, PCT and PLCR did not differ in patients with IBS compared with the control group. Conclusion We are of opinion that complete blood erythrocyte and platelet counts could not be used as prognostic marker in the diagnosis of IBS

Keywords

• Irritable bowel syndrome, hemoglobin, erythrocyte, platelet

İrritabl Bağırsak sendromlu Hastalarda Eritrosit ve Trombosit Hücre Sayılarının Değerlendirilmesi

Öz

Amaç: İBS, toplumdaki prevalansı oldukça yüksek olan, defekasyon değişiklikleriyle ilişkili abdominal ağrı ve/veya rahatsızlık sonucu yaşam kalitesini düşüren bir fonksiyonel gastrointestinal sistem hastalığıdır. İBS patogenezinde inflamasyon oluşumu ve bağışıklık sistemindeki değişikliklerin rol oynadığı bilinmektedir. Bu çalışmada İBS hastalarına ait eritrosit ve trombosit hücre sayılarını sağlıklı kontroller ile karşılaştırarak prognostik olarak değerlendirmeyi amaçladık. Materyal Metod: Çalışmamızda Namık Kemal Üniversitesi Tıp Fakültesi gastroenteroloji kliniğine başvuran 18-50 yaş arası 30 İBS hastası ve 30 sağlıklı kişinin dosya taraması yapıldı. Bu kişilerin demografik bilgileri ile birlikte eritrosit ve trombosit düzeyleri kaydedildi. Bulgular: İBS hastalarında RBC, HGB, HCT, MCV, MCH, MCHC, RDWCV ve RDWSD düzeylerinin kontrol grubuna göre anlamlı olarak değişmediği görülmüştür. Aynı şekilde PLT, MPV, PDW, PCT ve PLCR düzeylerinin de kontrol grubuna göre İBS hastalarında değişiklik göstermediğini bulduk. Sonuç: Tam kan eritrosit ve trombosit düzeylerinin İBS tanısında prognostik belirteçler olarak kullanılamayacağını düşünmekteyiz.

Anahtar Kelimeler

• Anahtar hemoglobin, eritrosit, trombosit kelimeler:İrritabl bağırsak sendromu

References

1. Saito YA, Talley NJ, L JM, Fett S, Zinsmeister AR, Locke GR. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil. 2003;15:687-94
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-91
3. Camilleri M, Heading RC, Thompson WG. Clinical mechanisms, perspectives, management of irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1407-30. diagnosis and
4. Kayahan H, Akarsu M, Ozcan MA, Demir S, Ates H, Unsal Bet al. Reticulated platelet levels in patients with ulcerative colitis. Int J Colorectal Dis. 2007;22:1429- 35.
5. Riordan SM, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol. 2006;22:669-73.
6. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol. 2012;18:5151- 63.
7. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic 2002;123:450-60. Gastroenterology.
8. Song CS, Park DI, Yoon MY, Seok HS, Park JH, Kim HJet al. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. Dig Dis Sci. 2012;57:1033-8.

9. Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci. 2009;54:842-7.
10. Zubcevic N, Mesihovic R, Zubcevic S. Usefulness of laboratory data in estimation of Crohn's disease activity. Med Arh. 2010;64:33-6.
11. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Kefalogiannis G, Niniraki M, Kouroumalis EA. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohns Colitis. 2011;5:295-300.
12. Khan K, Schwarzenberg SJ, Sharp H, Greenwood D, Weisdorf-Schindele S. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:325-9.
13. Beyazit Y, Koklu S, Tas A, Purnak T, Sayilir A, Kurt Met al. Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis. J Crohns Colitis. 2012;6:102-7.
14. Osada T, Ohkusa T, Okayasu I, Yoshida T, Hirai S, Beppu Ket al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2008;23 Suppl 2:S262-7.
15. Yesil A, Senates E, Bayoglu IV, Erdem ED, Demirtunc R, Kurdas Ovunc AO. Red cell distribution width: a novel marker of activity in inflammatory bowel disease. Gut Liver. 2011;5:460-7.
16. Ozturk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N, et al. Could platelet indices be new biomarkers for inflammatory bowel diseases? Eur Rev Med Pharmacol Sci. 2013;17:334-41.